Luxcel Biosciences Ltd.
Luxcel Biosciences Ltd.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2013.1.3-1 | Award Amount: 15.99M | Year: 2013
HeCaToS aims at developing integrative in silico tools for predicting human liver and heart toxicity. The objective is to develop an integrated modeling framework, by combining advances in computational chemistry and systems toxicology, for modelling toxic perturbations in liver and heart across multiple scales. This framework will include vertical integrations of representations from drug(metabolite)-target interactions, through macromolecules/proteins, to (sub-)cellular functionalities and organ physiologies, and even the human whole-body level. In view of the importance of mitochondrial deregulations and of immunological dysfunctions associated with hepatic and cardiac drug-induced injuries, focus will be on these particular Adverse Outcome Pathways. Models will be populated with data from innovative in vitro 3D liver and heart assays challenged with prototypical hepato- or cardiotoxicants; data will be generated by advanced molecular and functional analytical techniques retrieving information on key (sub-)cellular toxic evens. For validating perturbed AOPs in vitro in appropriate human investigations, case studies on patients with liver injuries or cardiomyopathies due to adverse drug effects, will be developed, and biopsies will be subjected to similar analyses. Existing ChEMBL and diXa data infrastructures will be advanced for data gathering, storing and integrated statistical analysis. Model performance in toxicity prediction will be assessed by comparing in silico predictions with experimental results across a multitude of read-out parameters, which in turn will suggest additional experiments for further validating predictions. HeCaToS, organized as a private-public partnership, will generate major socioeconomic impact because it will develop better chemical safety tests leading to safer drugs, but also industrial chemicals, and cosmetics, thereby improving patient and consumer health, and sustaining EUs industrial competitiveness.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.1.4-2 | Award Amount: 7.74M | Year: 2012
Organ transplantation is often the only life saving medical approach for several diseases, in spite of many associated problems (lack of organ donors, rejection, life-long heavy medication). The innovative therapeutic approach of the 21th century is focusing on bioartificial organs as an alternative solution.Tissue engineering and stem cell biology have uncovered groundbreaking opportunities for cellular re-programming, i.e., some cell types can be changed into a pluripotent stem cell (PSC) by over-expressing key transcription factors. These induced pluripotent stem cells (iPSC) share two key characteristics with embryonic stem cells (eSC): self-renewal and pluripotency (ability to differentiate to form any cell type in the human body). Crucially, they are generated from adult cells circumventing many ethical concerns associated with using human eSC. The discovery of human iPSC (hiPSC) enables the growth of an almost unlimited supply of a patients own cells, potentially conferring the ability to grow and regenerate tissues and organs from self, which is expected to resolve organ rejection-related issues. Similarly, recent developments in material science and nanobiotechnology resulted in engineered materials and devices (manipulated and controlled by physical and chemical means), with unique functional or analytical properties. NanoBio4Trans will merge hiPSC-, polymer hybrid scaffolds and biosensor technologies to develop new tools (beyond state-of-the-art) for use in transplantation and biomedical research. The international, trans-sectoral, and multidisciplinary consortium with complementary and leading expertise in material sciences, cell- and molecular biology, sensor technologies, and bioanalytics, aims at developing, optimising and validating a highly vascularised in vivo-like BAL as an extracorporeal bioartificial liver (EBAL), ready to be perfused with human blood plasma, and to be exploited in modern medical technology.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.3.3-03 | Award Amount: 7.40M | Year: 2012
BIOINTENSE is directed at addressing the challenges of low productivity and process intensity frequently hampering the implementation of bioprocesses in industry. For the future of the next generation of chemical processes in Europe it provides the opportunity not only to address intensification but also to enable this in a rapid manner. BIOINTENSE will make use of -technology to develop economically feasible intensified processes by integration of separation and process control, and to create tools to speed up the characterization and assessment of different process options and technologies and biocatalysts for increased process intensity. A strong focus lies in increasing the scale of biocatalytic and cascade reactions and to improve the fundamental factors that affect the economic feasibility. Both numbering up and scale-up methodologies will be tested. The BIOINTENSE consortium is ideally suited to address the challenges in KBBE.2012.3.3-03 and to meet the objectives, as it spans across disciplines, academia and industry: SMEs with a strong technology base in the areas of integrating separation in bioprocessing, biocatalyst development, immobilization, -reactor fabrication, and on-line monitoring will ensure top of the line industry focused research with a strong focus on scale-up and implementation. There is an urgent need for these challenges to be overcome to move towards a European Knowledge Based BioEconomy to exploit the environmental savings and economic potential if such bioprocesses were in place. Building on the recent advances in molecular biology, the time is now right to develop the necessary process engineering methodologies and implementation strategies to unlock the full potential of bioprocesses.
Luxcel Biosciences Ltd and MOCON Inc. | Date: 2011-06-22
An oxygen-sensitive probe having reduced cross-sensitivity to humidity and methods of manufacturing and using such probes to measure oxygen concentrations within an enclosed space. The probe includes a thin film of an oxygen-sensitive photoluminescent dye on a first major surface of a microporous wettable polyolefin support layer. The dye is preferably a solid state composition comprising the oxygen-sensitive photoluminescent dye embedded within an oxygen-permeable hydrophobic polymer matrix.
Luxcel Biosciences Ltd. | Date: 2011-07-18
Method of detecting the presence of thermoduric microorganisms in a product that includes the steps of (i) placing an aliquot A of a product into a vessel 10 equipped with a probe 30 sensitive to a thermoduric microorganism metabolite, (ii) pasteurizing the aliquot A within the vessel 10, (iii) incubating the pasteurized aliquot A within the vessel 10 for an incubation period, and (iv) periodically interrogating the probe 30 during the incubation period.
Luxcel Biosciences Ltd. | Date: 2011-08-17
A reference vessel and a method of validating operational integrity of an analytical instrument using the reference vessel. The reference vessel has certain design features that render it particularly suited for interrogation by a specific analytical instrument, and is equipped with a surrogate probe that generates a perceptible signal of known value when interrogated by that instrument regardless of the actual value of the variable in communication with the surrogate probe.
Luxcel Biosciences Ltd. | Date: 2011-11-22
Device (10) for rapid detection of biological oxygen consumption and method of classifying biological samples (e.g., positive and negative samples) (5) by detecting biological oxygen consumption. Each well (29) on a multi-well plate (20, 30) is hermetically sealed from the surrounding environment and other wells after deposit of a biological sample within the well by a cover plate (30) and an adherent gasket (40) sandwiched between the plates.
Agency: European Commission | Branch: H2020 | Program: SME-2 | Phase: SFS-08-2015 | Award Amount: 2.06M | Year: 2015
GreenLight is a ground-breaking new instrument / kit consumable platform to measure microbiological contamination, developed by international experts in the field of fluorescent oxygen sensing technology. This easy to use, reagent-free detection system is so sensitive, that a single bacteria cell can be measured in hours; rather than days using current agar plate methods. GreenLight is the first system to market that can be used end to end through the supply chain (from farm to fork). The unique sensor chemistry in the APCheck sensor vial, which is the core consumable of every GreenLight assay, allows contamination to be detected in any food or beverage product. The PROTECTDAIRY-F2F innovation business solution, leverages an existing international distribution network to realise 14m / 5 year new vial sales from launch in the dairy microbiology testing market, and position GreenLight for future growth targeting a 5% share of the much larger 2.5bn food and beverage testing market. To achieve these sales, we will optimise and scale vial manufacture, to ensure competitive pricing of 2.50 per test while maintaining a 40% profit margin at high volumes. We will position GreenLight as the microbiology testing platform of choice for the dairy industry, by integrating a complete suite of approved test applications, together with real-time traceability, trend analysis, early warning and alert across the entire supply chain.
LUXCEL BIOSCIENCES Ltd | Date: 2012-12-05
Flexibly deployable, discrete, target-analyte sensitive particulate probes and methods of manufacturing and using. The probes each comprise a porous scaffold particle coated with an optically-active, target-analyte sensitive material. The scaffold particle has at least one of (i) a volume of 0.5 to 500 mm^(3), and (ii) a largest dimension of 2 to 20 mm.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: FTIPilot-01-2016 | Award Amount: 3.31M | Year: 2016
The healthcare industry is experiencing unprecedented rates of drug failure, long development times and high costs - because current lab tests and disease models (in vitro) dont adequately predict drug effect in the patient (in vivo). To address this Challenge, three leading EU SMEs; Luxcel Biosciences Ltd, Axiogenesis AG and BMG Labtech GmbH, are partnering to bring to market, a fully integrated targeted metabolomics Test Platform, comprising physiologically relevant in vitro cell assays and easy to use test kits, configured for use with the multimode fluorescence plate reader; instrumentation, which is installed in, or else is easily accessible to every cell biology lab globally. The innovation Solution is made possible by Luxcels unique and patented optical nanosensor technology, and its integration to create entirely new functionally-connected in vitro tests. The scope of the project is to finalize development of the cell-based assay platform towards market introduction, productise, pilot and demonstrate it with key opinion leaders; for modular product launch through the project and full launch early 2019. Leveraging existing global sales channels, the three industrial partners are targeting revenues of EUR 15 million by 2023. In total, about 24-29 new jobs will be created by 2023; with 6 new jobs during the project. All three SMEs are passionate about the MetaCell-TM solution, and expect that a successful outcome will see them positioned as No. 1 in their respective fields in Europe and internationally.